Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Novavax Inc (NVAX) Price & Performance

ProShares UltraShort Bloomberg Natural Gas ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

ProShares UltraShort Bloomberg Natural Gas ETF vs Novavax Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.78 (market cap $141.25M), while Novavax Inc trades at $12.94 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 12.9× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Novavax Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Novavax Inc for 59 Days on average.

KOLDNVAX
Market Cap
$141.25M$1.82B
Volume
5,492,3676,198,505
Sector
Leveraged / InverseHealth
52-Week High
$49.39$12.56
52-Week Low
$13.58$6.22
Typical Hold Time
10 Days59 Days
Enterprise Value
—$1.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares UltraShort Bloomberg Natural Gas ETF

KOLD is trading at $24.475, down 1.47% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from record-high natural gas production and mild weather forecasts that are weighing on energy sector sentiment. Recent news highlights geopolitical tensions in the Middle East and supply dynamics affecting natural gas markets, creating volatility for energy-related investments.

The outlook remains cautious given the bearish technical indicators and fundamental pressures from oversupply conditions in natural gas markets. Investment opportunities exist for contrarian investors betting on geopolitical risk premiums, but risks include continued production growth and weather-dependent demand uncertainty that could pressure energy sector performance in the near term.

Novavax Inc

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KOLD
100% Buy0% Sell
Avg holding period · 10 Days
NVAX
55% Buy45% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About ProShares UltraShort Bloomberg Natural Gas ETF

KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.

Read more on KOLD →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →